Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07111494 · ClinicalTrials.gov registry record · Phase 4
Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial
A Phase 4 study, sponsored by Medical College of Wisconsin.
- Not yet
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
NCT07111494 is a Phase 4 study that has not yet begun recruiting, run by Medical College of Wisconsin. The registered enrollment target is 22 participants.
The verdict
NCT07111494, a Phase 4 study, has not yet begun recruiting, sponsored by Medical College of Wisconsin.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
Study Summary
Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutrition counseling can better treat individuals with Psoriatic Arthritis who are also needing treatment for obesity and type 2 diabetes. The main objectives it aims to answer are: To assess disease outcomes of PsA patients undergoing treatment for concomitant obesity and type 2 diabetes with GLP-1 analogs vs nutrition counseling. To assess effectiveness as measured by clinical and patient reported outcome measures in patients treated with GLP-1 and nutrition counseling. Participants will be randomized to receive a GLP-1 or nutrition counseling. Participants will be asked to come to the study center at most four times during a 24-week period. During this time participants will be asked to fill out questionnaires, receive a physical exam, and have their blood drawn.
Interventions
- OTHER Nutrition Counseling
- DRUG GLP-1 agonists
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2028-10-15 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07111494
The ClinicalTrials.gov registry entry for NCT07111494 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nutrition Counseling is the first listed.
NCT07111494 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07111494 about?
NCT07111494 is a clinical study titled "Impact of Glucagon-like Peptide-1 (GLP-1) Analogs on Disease Outcomes in Psoriatic Arthritis: A Pragmatic Randomized Controlled Trial". Psoriatic arthritis (PsA) is a chronic inflammatory condition that affects the joints but can also have an effect on multiple parts of the body. This study will assess if the effectiveness of Glucagon-like peptide-1 (GLP-1) medications used to treat type 2-diabetes and weight management, or nutritio...
What is the current status of trial NCT07111494?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2025-10-15. Estimated completion is 2028-10-15.
What interventions are being tested in trial NCT07111494?
The interventions under investigation include: Nutrition Counseling (OTHER), GLP-1 agonists (DRUG).
Who is sponsoring clinical trial NCT07111494?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.